Products for Research Use Only
RegisterLogin

SH514

CAT: 0804-HY-172085-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-172085-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SH514 is an orally active IRF4 inhibitor (IC50 = 2.63 μM) . SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM) . SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1, Cyclin D1, Cyclin E1, and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX. SH514 effectively inhibits the proliferation of multiple myeloma tumors [1].
UNSPSC
12352005
Target
CDK; c-Myc; DNA/RNA Synthesis; IFNAR
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@]12CC[C@@]3([H])[C@@]([H])(C(C=C4C(C)(C(C(C#N)=C[C@@]43C)=O)C)=O)[C@]1([H])CC[C@@H]2[C@@H](C(NC5=CC=C(C=C5)OC)=O)C
Molecular Formula
C32H38N2O4
Molecular Weight
514.66
References & Citations
[1]Zhang JZ, et al. Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma. Eur J Med Chem. 2025 Mar 5;285:117240.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BUP22041-01SH514

Popular Products